ILROG COVID-19大流行期间血液系统恶性肿瘤放疗应急指南
国际淋巴瘤放射肿瘤学组(ILROG)针对COVID-19大流行导致治疗资源受限及需减少患者和工作人员暴露的问题,提出替代放疗方案建议,强调通过增加单次剂量、减少每日治疗次数来维持疗效与安全,并讨论部分血液肿瘤类别中推迟或省略放疗的选项。
要点
- 应急指南建议通过增加单次剂量、减少治疗次数来维持疗效与安全
- 方案调整需符合可接受的放射生物学参数和临床耐受性
- 部分血液肿瘤类别可考虑推迟或省略放疗
核心结论
- 在COVID-19大流行期间,ILROG建议采用替代放疗方案以应对资源限制并减少暴露。
研究设计与样本
- ILROG工作组基于放射生物学参数和临床耐受性制定应急推荐。
主要发现
- 强调通过增加单次剂量、减少每日治疗次数来维持临床疗效与安全。
- 讨论了部分血液肿瘤类别中推迟或省略放疗的选项。
临床怎么用
- 在资源受限或需减少暴露时,可考虑增加单次剂量、减少治疗次数的放疗方案。
- 根据放射生物学参数和临床耐受性评估替代方案的可行性。
- 对部分血液肿瘤类别可评估推迟或省略放疗的可行性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The International Lymphoma Radiation Oncology Group (ILROG) guidelines for using radiation therapy (RT) in hematological malignancies are widely used in many countries. The emergency situation created by the COVID-19 pandemic may result in limitations of treatment resources. Furthermore, in recognition of the need to also reduce the exposure of patients and staff to potential infection with COVID-19, the ILROG task force has made recommendations for alternative radiation treatment schemes. The emphasis is on maintaining clinical efficacy and safety by increasing the dose per fraction while reducing the number of daily treatments. The guidance is informed by adhering to acceptable radiobiological parameters and clinical tolerability. The options for delaying or omitting RT in some hematological categories are also discussed.
引用
- Yahalom J, Dabaja BS, Ricardi U, et al. ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic. Blood. 2020. PMID: 32275740. doi:10.1182/blood.2020006028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。